Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura

Boothe, James T.; Budd, G. Thomas; Smolkin, Matthew B.; Patrick, C.

doi:10.1159/000484041

Cited by 13 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The therapeutic antibody was well tolerated and did not generate significant adverse effects over the therapeutic cycle. 97 Overall, the proof of concept regarding the therapeutic use of anti-PD-1 monoclonal antibody is well established. It is expected to be effective in cancers where evasion of the immune system plays a fundamental role in tumor progression.…”

Section: Evasion Of the Immune Response: Aberrant Communication Betwementioning

confidence: 99%

Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies

Cervantes‐Villagrana

Albores-García

Cervantes-Villagrana

et al. 2020

Sig Transduct Target Ther

161

112

View full text Add to dashboard Cite

Normal cells are hijacked by cancer cells forming together heterogeneous tumor masses immersed in aberrant communication circuits that facilitate tumor growth and dissemination. Besides the well characterized angiogenic effect of some tumor-derived factors; others, such as BDNF, recruit peripheral nerves and leukocytes. The neurogenic switch, activated by tumor-derived neurotrophins and extracellular vesicles, attracts adjacent peripheral fibers (autonomic/sensorial) and neural progenitor cells. Strikingly, tumor-associated nerve fibers can guide cancer cell dissemination. Moreover, IL-1β, CCL2, PGE 2 , among other chemotactic factors, attract natural immunosuppressive cells, including T regulatory (Tregs), myeloid-derived suppressor cells (MDSCs), and M2 macrophages, to the tumor microenvironment. These leukocytes further exacerbate the aberrant communication circuit releasing factors with neurogenic effect. Furthermore, cancer cells directly evade immune surveillance and the antitumoral actions of natural killer cells by activating immunosuppressive mechanisms elicited by heterophilic complexes, joining cancer and immune cells, formed by PD-L1/PD1 and CD80/CTLA-4 plasma membrane proteins. Altogether, nervous and immune cells, together with fibroblasts, endothelial, and bone-marrow-derived cells, promote tumor growth and enhance the metastatic properties of cancer cells. Inspired by the demonstrated, but restricted, power of anti-angiogenic and immune cell-based therapies, preclinical studies are focusing on strategies aimed to inhibit tumor-induced neurogenesis. Here we discuss the potential of anti-neurogenesis and, considering the interplay between nervous and immune systems, we also focus on anti-immunosuppression-based therapies. Small molecules, antibodies and immune cells are being considered as therapeutic agents, aimed to prevent cancer cell communication with neurons and leukocytes, targeting chemotactic and neurotransmitter signaling pathways linked to perineural invasion and metastasis.

show abstract

Section: Evasion Of the Immune Response: Aberrant Communication Betwementioning

confidence: 99%

Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies

Cervantes‐Villagrana

Albores-García

Cervantes-Villagrana

et al. 2020

Sig Transduct Target Ther

161

112

View full text Add to dashboard Cite

show abstract

“…In patients treated with first-line anthracyclines we can consider using pazopanib. Promising results can also be found for other molecular-guided drugs [11,12] and immunotherapy [13]. However, further research is needed for larger groups of patients, which could confirm the effectiveness of these therapies.…”

Section: Immunotherapymentioning

confidence: 99%

“…In a case report of a 50-year-old patient with a diagnosis of malignant form of SFT of the pleura, after many lines of systemic treatment (carboplatin + paclitaxel, gemcitabine + docetaxel, temozolomide + bevacizumab), treatment with pembrolizumab was introduced [13]. The drug was administered in two doses at 2 mg/kg IV every three weeks.…”

Section: Immunotherapymentioning

confidence: 99%

See 1 more Smart Citation

Advanced solitary fibrous tumour of the pleura — a case report and literature review

2019

View full text Add to dashboard Cite

Advanced solitary fibrous tumour of the pleura -a case report and literature review ABSTRACT The solitary fibrous tumour (SFT) is a rare tumour, which usually occurs in the pleura. Patients with an advanced SFT have a poor prognosis. The treatment options for recurrent disease are especially limited. We present the case of a 55-year-old female patient with a malignant SFT of the pleura, who received conventional chemotherapy and targeted therapy. This paper focuses on systemic therapy in the treatment of metastatic SFT.

show abstract

“…Bei einem Patienten mit fortgeschrittenem malignem SFTP, dessen Tumor eine positive Tumorexpression für PD-L1 (2+, 5 %) zeigte, wurde eine Immuntherapie mit Pembrolizumab durchgeführt. Der Tumor zeigte ein sofortiges und fast vollständiges Therapieansprechen [27].…”

Section: Neoadjuvante Und Adjuvante Therapieunclassified

Monströser solitärer fibröser Tumor der Pleura

et al. 2021

View full text Add to dashboard Cite

ZusammenfassungLokalisierte, solitäre fibröse Tumoren sind eine seltene Entität und finden sich meist im Thorax, können aber auch in Leber, Haut, Meningen, am Peritoneum und Perikard auftreten. Aufgrund des vielgestaltigen mikromorphologischen Erscheinungsbildes ist die Sicherung der Diagnose oftmals schwierig. Entscheidend ist die histopathologische Begutachtung mit differenzierter Immunhistochemie. Die chirurgische Resektion der lokalisierten, solitären fibrösen Tumoren ist die Therapie der Wahl. Die Rezidiv- und Metastasenrate ist abhängig von der histologischen Dignität insgesamt sehr gering. Kontinuierliche Nachsorgeuntersuchungen sind indiziert.Wir berichten über eine 76-jährigen Patientin mit einem monströsen solitären fibrösen Tumor der Pleura, die seit einigen Wochen über Belastungsdyspnoe und stechende Schmerzen rechts thorakal klagte. Computertomografisch zeigte sich eine heterogene Raumforderung mit ca. 22 cm Durchmesser im Mittel- und Unterfeld des Thorax mit Kompression des Zwerchfells und des Mediastinums. Der Tumor wurde über eine doppelte Thorakotomie im 5. und im 8. Interkostalraum vollständig reseziert. Intraoperativ zeigte sich der Tumor zum Mittellappen gestielt. Um den Tumor vollständig zu entfernen, wurde zusätzlich eine Keilresektion aus dem Mittellappen durchgeführt. Der Tumor wog 2,4 kg. Die Diagnose eines solitären fibrösen Tumors der Pleura wurde histologisch und immunhistochemisch gestellt. Postoperativ hat sich die Lunge vollständig entfaltet. Bei der 3-monatigen Nachuntersuchung zeigte sich kein Nachweis eines Rezidivs. Die klinische Symptomatik, Diagnosestellung, Therapieoptionen, Rezidivrisiko und die Prognose dieser Tumore werden aufgezeigt und entsprechend der Literatur diskutiert.

show abstract

Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura

Cited by 13 publications

References 16 publications

Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies

Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies

Advanced solitary fibrous tumour of the pleura — a case report and literature review

Monströser solitärer fibröser Tumor der Pleura

Contact Info

Product

Resources

About